Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.

ABSTRACT:

Background

Nivolumab plus ipilimumab has shown survival benefits as first-line treatment for unresectable hepatocellular carcinoma (HCC) but their high cost raises concerns about value. This study assessed the cost-effectiveness of nivolumab plus ipilimumab compared with lenvatinib or sorafenib from a United States (US) health care payer perspective.

Methods

A partitioned survival model was developed using data from the CheckMate 9DW trial with a 10-year horizon. Costs and outcomes were discounted by 3% annually. Clinical inputs were derived from CheckMate 9DW trial, and cost inputs were obtained from public databases and published studies. Primary outcomes were quality-adjusted life years (QALYs), total costs, life years (LYs), and incremental cost-effectiveness ratios (ICE

SUBMITTER: Luo J 

PROVIDER: S-EPMC12860969 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature